Oric Pharmaceuticals

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023:  ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 11:15 a.m. PT.

ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Core Scientific Inc

ProQR Therapeutics

What you need to know about trading penny stocks as the year ends The post New Years Penny Stocks Trading Advice: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

New Years Penny Stocks Trading Advice: 3 Tips

Pfizer

ORIC inks a collaboration deal with Pfizer for a phase II study evaluating ORIC-533 in combination with the latter's elranatamab in multiple myeloma. Stock up in after-hours trading.

ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study

Shares of Oric Pharmaceuticals Inc. ORIC, +2.04% soared about 56% in premarket trading on Thursday, the day after the company said it will collaborate with Pfizer Inc. PFE, +0.66% to develop a multiple myeloma therapeutic candidate. Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a total of $25 million.

Oric's stock rallies on multiple myeloma deal with Pfizer

ORIC Pharmaceuticals (NASDAQ: ORIC ) stock is rocketing higher after the company revealed a collaboration deal with Pfizer (NYSE: PFE ). The big news here is ORIC Pharmaceuticals and Pfizer working together on the development of ORIC-533.

ORIC Pharmaceuticals (ORIC) Stock Rockets 58% on Pfizer Deal

ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented preclinical ORIC-533 data demonstrating a potential best-in-class CD73 inhibitor profile for the treatment of multiple myeloma.

ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 5:35 p.m. GMT.

ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a preclinical poster presentation on ORIC-533 at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, LA.

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023.

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma,  ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 8:00 a.m. ET.

ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Dominic Piscitelli, chief financial officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7:00 a.m. ET.

ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H2023

ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting.

ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Asana

Ford Motor Company

GameStop

Eastman Kodak

Revolution Medicines

SoFi Technologies

Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revolution Medicines (NASDAQ:RVMD) Sofi Technologies (NASDAQ:SOFI) The post 7 Stocks That Insiders Are Buying Now. Should You?

7 Stocks That Insiders Are Buying Now. Should You?

ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.

ORIC Stock Plunges on Discontinuation of Oncology Candidate

The company discontinued development of its lead clinical program.

Why ORIC Pharmaceuticals Stock Is Crashing Today

ORIC Pharmaceuticals Inc (NASDAQ: ORIC) has decided to discontinue the further development of ORIC-101 after interim analyses from the two Phase 1b studies, wherein ORIC-101 did not demonstrate sufficient clinical activity. The dose-expansion portion of the Phase 1b trial of ORIC-.

Why ORIC Pharmaceuticals Shares Are Plunging Today

ORIC Pharmaceuticals, Inc.'s (ORIC) CEO Jacob Chacko on Q4 2021 Results - Earnings Call Transcript

Announces decision to discontinue development of ORIC-101

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results and provide an operational update on Monday, March 21, 2022, at 5:00 p.m. ET.

ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call

ORIC-533 oral presentation and poster presentation to highlight potential of small molecule inhibitor of CD73 as a treatment for multiple myeloma

News for Oric Pharmaceuticals Stock (ORIC)